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C O M M E N T

Emerging EPA Regulation of
Pharmaceuticals in the Environment
by Gabriel Eckstein
Gabriel Eckstein is a Professor of Law, Texas Wesleyan University,.
and Of Counsel, Sullivan & Worcester.

A

recent report by the Office of Inspector General (OIG) of the U.S.  Environmental Protection Agency (EPA) criticized EPA for failing to
take regulatory action regarding pharmaceuticals found
in the nation’s freshwater resources.  The May 25, 2012,
report—entitled EPA Inaction in Identifying Hazardous
Waste Pharmaceuticals May Result in Unsafe Disposal (OIG
Report)1—disapproved of EPA’s lack of progress in determining whether certain pharmaceuticals found in surface,
ground, and drinking water qualify as hazardous waste, as
well as in establishing an evaluation and regulatory process
for pharmaceutical wastes. As a result of the report, EPA
is now considering mechanisms for assessing and regulating the presence of certain pharmaceutical products in the
environment as hazardous wastes under the Resource Conservation and Recovery Act (RCRA).2

I.

Background

In recent years, serious questions have been raised regarding the environmental and health impacts of the multitudes
of pharmaceutical and personal care products (PPCPs)
that have accumulated in the nation’s freshwater resources. 
Numerous studies have suggested that exposure to certain
PPCPS, such as antibiotics and endocrine disruptors, may
result in a variety of adverse health impacts in humans;
other research has more conclusively established the detrimental effects that even minute concentrations of certain drugs can have on aquatic species. The most obvious
pathway by which humans can be exposed to PPCPs is by
consuming contaminated water. Exposure, however, may
also occur through the consumption of fish and shellfish
that have bioaccumulated PPCPs, or through swimming
or bathing in water containing PPCPs.
The wastewater discharge and treatment communities
have been increasingly concerned about PPCPs in light of
their ability to persist or only partially degrade in water and
1.	
2.	

Rep.  No.  12-P-0508, available at http://www.epa.gov/oig/reports/2012/
20120525-12-P-0508.pdf.
42 U.S.C. §§6901-6992k, ELR Stat. RCRA §§1001-11011.
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during the wastewater treatment process and, as a result,
the growing presence of PPCPs in treated wastewater effluent that reaches streams, lakes, groundwater, and seawater. Similarly, freshwater treatment operators are becoming
alarmed about their ability to provide safe freshwater to
the nation’s population and the steps they may have to take
to ensure water quality.  Moreover, producers of PPCPs
and generators of large quantities of PPCP wastes, such as
hospitals and nursing homes, are also becoming concerned
about the regulation of these wastes.
PPCPs are an extremely diverse group of chemicals used
in health care, cosmetics, hygiene, veterinary medicine,
and agriculture. Researchers have estimated that the number of commercially available PPCP substances worldwide
may be as high as six million. PPCPs are ubiquitous pollutants, entering the environment worldwide due to widely
dispersed usage in industry and agriculture, as well as by
individuals at home. Sources of PPCPs include human and
animal feces and urine, hospital and medical wastes, wastes
from industrial and agricultural processes, the inappropriate disposal of unwanted PPCPs products, urban runoff,
and leachate from landfills. These contaminants are rarely
treated or removed in the wastewater treatment process
and typically remain in waters discharged from wastewater
treatment plants into receiving streams and lakes, as well
as in solid and liquid wastes applied to lands designated as
application sites.

II.

Regulating Pharmaceutical Waste

The U.S.  Congress has not adopted legislation specifically aimed at PPCPs generally, or pharmaceutical
products solid waste streams specifically.  Nevertheless,
certain pharmaceutical wastes are subject to regulation
under RCRA. Under that statute, EPA (or a state agency
authorized by EPA) regulates the generation, storage,
transportation, treatment, and disposal of solid wastes
that are deemed to be hazardous.  Facilities, including hospitals, nursing homes, pharmaceutical dispensers, and other health-related operations that generate
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between 100-1,000 kilograms (kg) (220-2,200 pounds
(lbs.)) of hazardous waste per month, or up to 1 kg (2.2
lbs.) of acute hazardous waste per month, must comply
with RCRA’s hazardous waste provisions. Those include
approved containers for transporting hazardous wastes,
transport by designated hazardous waste transporters,
and disposal by permitted hazardous waste disposal
facilities. Facilities that generate 1,000 kg (2,200 lbs.) or
more of hazardous waste per month, or 1 kg (2.2 lbs.)
or more of acute hazardous waste per month, are subject
to additional requirements. Disposal of hazardous waste
in municipal waste landfills, municipal incinerators, or
medical waste plants is strictly prohibited under RCRA.
EPA’s RCRA regulations set forth a number of tests for
identifying wastes as hazardous. Wastes may be classified
as hazardous if they are found to be ignitable, corrosive,
toxic, or reactive.  While most PPCP waste products are
not ignitable, some substances (like solvents) can be corrosive, numerous PPCPs have been found toxic to humans
as well as plants and animals, and many PPCPs react with
other substances to produce toxic or otherwise harmful
compounds. EPA can also classify wastes as hazardous by
identifying those that can be fatal to humans or animals
above certain thresholds or doses (P-list substances), and
those that either exhibit any of the four hazardous characteristics noted above or contain a toxic constituent (e.g.,
chemical compounds or elements that have been shown to
have toxic, carcinogenic, mutagenic, or teratogenic effects
on humans or other life forms) capable of posing a “substantial present or potential hazard to human health or the
environment when improperly treated, stored, transported,
or disposed of, or otherwise managed”3 (U-list substances). 
Unfortunately, the vast majority of PPCPs have yet to be
evaluated for any hazardous qualities.
According to the OIG Report, EPA in 1980 identified
31 pharmaceutical substances that met the hazardous waste
criteria for listing under RCRA.4 Since that initial designation, while the Food and Drug Administration approved
hundreds of new drugs (an average of 30 drugs each year
since 1996), EPA has not updated its RCRA pharmaceuticals list. Moreover, EPA has not established a process for
regularly identifying and reviewing new or existing pharmaceuticals that may qualify for regulation as hazardous
waste products.  In contrast, the National Institute for
Occupational Safety and Health (NIOSH) has identified
more than 160 drugs that it states should be handled as
hazardous materials,5 while the Occupational Safety and
3.	
4.	

5.	

42 U.S.C. §6903(5), ELR Stat. RCRA §6903(5).
According to the Health Care Environmental Resources Center (available at
http://www.hercenter.org/hazmat/pharma.cfm#listed), seven pharmaceutical substances are found under EPA’s P-list (Arsenic trioxide, Epinephrine,
Nicotine, Nitroglycerin, Physostigmine, Physostigmine salicylate, and Warfarin >0.3%), and 24 are included in the Agency’s U-list (Chloral Hydrate,
Chlorambucil, Chloroform, Cyclophosphamide, Daunomycin, Dichlorodifluromethane, Diethylstilbestrol, Formaldehyde, Hexachlorophene,
Lindane, Melphalan, Mercury, Mitomycin C, Paraldehyde, Phenacetin,
Phenol, Reserpine, Resorcinol, Saccharin, Selenium sulfide, Streptozotocin,
Trichloromonofluromethane, Uracil mustard, Warfarin <0.3%).
U.S. Department of Health & Human Services, NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings
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Health Administration (OSHA) lists 61 pharmaceuticals
on its own hazardous drug list.6 According to the OIG:
RCRA hazardous waste regulations are not keeping up
with drug development and the potential hazards they
may pose if mismanaged and disposed without the necessary protections to human health and the environment. 
Without an established process to review pharmaceuticals,
EPA cannot ensure that it has identified pharmaceutical
contaminants that may pose a hazardous risk to human
health and the environment.7

In 2008, EPA attempted to address this deficiency by
proposing to add hazardous waste pharmaceuticals to the
Universal Waste Rule (UWR) under RCRA.  The UWR
is an EPA program designed to streamline the management and disposal of some of the more commonly occurring hazardous wastes, like spent batteries, pesticides, and
mercury-containing equipment. EPA believed that adding
hazardous waste pharmaceuticals to this program would
“facilitate better management of pharmaceutical wastes by
streamlining the generator requirements and encouraging
generators of hazardous pharmaceutical wastes to manage
them under the provisions of the UWR, which ensures
that these hazardous pharmaceutical wastes are properly
disposed of and treated as hazardous wastes.”8 Following
substantial negative comments, the Agency withdrew the
proposal, concluding that it would have to repropose a new
rule to adequately respond to the various concerns.  EPA
has yet to follow through on this effort.

III. The OIG’s Concerns
In its report evaluating EPA pharmaceutical-related activities, the OIG faulted the Agency for failing to update its
list of pharmaceuticals that met the hazardous waste criteria under RCRA, as well as for failing to establish a process
by which the Agency can regularly assess and identify new
or existing pharmaceuticals that may qualify for regulation. Highlighting the efforts of the NIOSH and OSHA
and considering those agencies’ lists as a valid starting
point, the OIG identified eight chemicals found in certain
pharmaceuticals that were not regulated by EPA, but that
met EPA criteria for regulation as “acute hazardous waste.”
It also identified three pharmaceuticals currently regulated
by EPA under RCRA’s “toxic” criteria (U-list), but that
actually met RCRA’s “acutely” toxic standards (P-list). The
OIG also distinguished 21 other pharmaceuticals that currently are not regulated by EPA, but which may qualify as
“toxic” under EPA’s RCRA criteria.
In addition, the OIG Report noted that according to
EPA itself, many “health care workers, retail pharmacy

6.	
7.	
8.	

2012, available at http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012150.pdf.
U.S. Department of Labor, OSHA Technical Manual (OTM), Section VI:
Ch. 2, App. VI: 2-1, http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.
html.
Supra note 1, at 7.
73 Fed. Reg. 73519 (Dec. 2, 2008).
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employees, and other pharmaceutical generators are often
unfamiliar with or confused by RCRA hazardous waste
management requirements, prompting them to improperly
dispose of hazardous pharmaceuticals as municipal or bulk
wastes.”9 While the lack of awareness and understanding
may be the product of an inadequate, inefficient, and/or
antiquated system, it has not stopped some states and EPA
regional offices from imposing fines and citations. In April
2012, for example, California settled with retail drugstore
giant CVS Pharmacy for $13.75 million on claims that
the national chain illegally disposed of pharmaceutical
and other hazardous waste.  Two months later, California settled with Costco for $3.6 million on similar allegations. In 2010, the New York Attorney General settled
with five health care facilities after investigations showed
that they released pharmaceutical waste into the New York
City Watershed. In 2009, EPA Region 7 issued a $50,000
fine to a hospital and required the facility to implement
programs to manage pharmaceutical and other waste at a
cost of nearly $500,000. In 2003 and 2004, EPA Region
2 issued fines ranging from $40,000 to $280,000 after
identifying violations at a number of health care facilities. 
Similar enforcement and outreach efforts appear to be on
the rise elsewhere across the country.

IV.

The OIG’s Recommendations

In its conclusion, the OIG asserted: “If EPA’s hazardous
waste rules do not keep up with new drug development
or ensure that regulated entities understand and comply
with their obligations, uncertainties about human health
and environmental risks from hazardous pharmaceuticals are likely to grow.”10 Accordingly, it recommended
that EPA’s Assistant Administrator for Solid Waste and
Emergency Response identify and review existing pharmaceuticals to determine whether they qualify for regulation as hazardous waste, as well as to establish a process
for reviewing new pharmaceuticals to determine whether
they qualify for regulation as hazardous waste.  In addition, it advised the Agency to develop a nationally consistent outreach and compliance assistance plan to help
states address challenges that health care and other facilities may have in complying with RCRA regulations for
managing hazardous waste pharmaceuticals.

V.

EPA’s Response11

In its response to the OIG’s Report, EPA contended that
the OIG failed to fully appreciate the complexities of listing a chemical as a commercial chemical product. It also
suggested that resources to evaluate whether new drugs
9.	 Supra note 1, at 9.
10. Supra note 1, at 9.
11. Memorandum, Response to EPA Office of Inspector General Report, EPA
Inaction in Identifying Hazardous Waste Pharmaceuticals May Result in Unsafe
Disposal (Rep.  No.  12-P-0508, May 25, 2012), Aug.  24, 2012, available
at http://www.epa.gov/oig/reports/2012/12-P-0508_Agency%20Response.
pdf.
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and other substances qualify for regulations, as well as
to update existing and formulate new regulations, are
becoming more limited given the ever-increasing pace of
technology and development.  Nevertheless, the Agency
agreed “that pharmaceuticals are a category of chemicals
that need attention.”12
With regard to the OIG’s recommendations, however,
EPA’s response was somewhat noncommittal.  It stated
that the Agency “will consider the appropriate next steps
to take given significant resource constraints and competing priorities”13 and that further actions the Agency could
pursue may include a process to review newly developed
pharmaceuticals as well as to “propose revisions to RCRA
regulations to more effectively address hazardous waste
pharmaceuticals in the health care sector.”14 In responding
to the OIG’s third recommendation pertaining to outreach
and compliance assistance programs, EPA stated that it is
now “developing major revisions to the hazardous waste
regulations to make them more effective for the health care
sector and the hazardous waste pharmaceuticals they generate” with the aim of helping “states with implementation
and the regulated community with compliance with the
RCRA regulations for hazardous waste pharmaceuticals.”15
Whether those major revisions will address the OIG’s concerns related to the identification and evaluation of existing and new pharmaceuticals or only implementation and
compliance with the existing program remains to be seen. 
The Agency anticipates that it will publish a proposed rule
in March 2013.

VI. Concluding Thoughts
Given the current trends, it is very likely that pharmaceutical wastes will be subject to more regulations in the
near future.  The presence and fate of such substances in
the nation’s waters is raising serious concerns nationwide
that are not likely to subside. EPA is currently attempting
to formulate processes and mechanisms to respond to this
apparent threat and to build on the existing, albeit limited,
RCRA program. It is also possible that EPA will revisit its
2008 effort, which focused on the UWR under RCRA, as
part of its regulatory efforts. Whatever the Agency formulates will be of significant interest to numerous industries
and sectors, particularly the water discharge and treatment
communities, producers of pharmaceuticals, and generators of pharmaceutical wastes. EPA, however, also will be
watched closely by the producers of personal care products
and generators of personal care product wastes, as well as
the general public and the various states who have already
indicated their growing concerns with the potential health
and environmental threats posed by these contaminants.
Nevertheless, as EPA (and, potentially, Congress and
state legislatures across the country) considers the vari12.
13.
14.
15.

Id. at 1.
Id. at 2.
Id.
Supra note 1, at 18.

ous programmatic and regulatory options that might be
pursued, it may be prudent to take a step back and ask
a number of rather simplistic but obvious questions.  Is
it truly possible to develop a coherent regulatory process
that will adequately assess whether the tens of thousands
of pharmaceutical waste products (let alone the millions
of different PPCP substances and waste products) require
regulation? If yes, could a regulatory program like RCRA
devise, implement, and monitor the multitude of disparate
disposal, removal, and treatment mechanisms that will
have to be developed for each of the multitude of classes
and categories of pharmaceuticals or personal care products? The magnitude of the challenge is daunting.
It is noteworthy that RCRA is not the only potentially
relevant federal statute for regulating the presence and fate
of PPCPs in the environment. Other statutes that may be
applicable include the Clean Water Act (CWA),16 the Safe
Drinking Water Act (SDWA),17 and the Toxic Substances
Control Act (TSCA).18 While each of these approaches
may have its own allures and virtues, and each one offers
unique mechanisms intended to protect human and environmental health, like RCRA, all of them suffer from the
tremendous challenge of regulating the massive quantity of
disparate PPCP substances and wastes that now infest the
nation’s freshwater resources. Additionally, even assuming
that large-scale wastewater or freshwater treatment techniques and systems can be developed to comply with any
of these statutory schemes as a means of controlling the
plethora of PPCPs, the cost could be staggering.  As one
researcher noted: “Although the public may want pure
water, people are not prepared to pay what it would actually cost even if sufficient technology did exist.”19
In a recent report—“Alternative Strategies for Addressing the Presence and Effects of Pharmaceutical and Personal
Care Products in Fresh Water Resources”20 —published in
the Denver Water Law Review, the present author and a

colleague offer an alternative or supplementary approach
to the regulation of PPCP wastes. Rather than solely focusing on the presence of PPCPs in the environment through
regulations limiting such contamination, the relevant
PPCP industries and professions, as well as various regulatory bodies, should investigate actions designed to remove
or minimize the presence of PPCPs before they reach the
environment. For example, drugs and personal care products could be designed to minimize the human and animal
excretion of PPCP wastes, which would then minimize the
volume of PPCPs that enter the environment.  Likewise,
changing the delivery mechanisms or tailoring dosages to
individual patients could reduce excreted PPCPs. In addition, greater efforts could be made for the proper disposal
of PPCPs amongst the regulated community as well as the
general public.  Other options include reducing the need
for PPCPs through the use of non-PPCP alternative as well
as nutrition and health maintenance programs.
The presence and fate of PPCPs in the environment, and
especially in surface, ground, and drinking water resources,
is a complicated problem that will not be quickly addressed. 
Responding to the various concerns will likely require multiple, complementary solutions, including reducing PPCPs
in various products, treating PPCP wastes prior to discharge into the waste stream and the environment, proper
disposal programs, monitoring systems, and even changing peoples’ habits.  Whether these can be implemented
through industry and community efforts, or through the
regulatory process, remains to be seen. Given the massive
numbers of PPCPs produced globally, the complexities
involved in determining whether any particular PPCP or
combination of PPCPs may be harmful to people or the
environment, and the scientific and political challenges of
formulating appropriate responses, it is safe to say that this
issue will be with us for years to come.

16.
17.
18.
19.

33 U.S.C. §§1251-1387, ELR Stat. FWPCA §§101-607.
42 U.S.C. §§300f to 300j-26, ELR Stat. SDWA §§1401-1465.
15 U.S.C. §§2601-2692, ELR Stat. TSCA §§2-412.
Keith J. Jones, Endocrine Disruptors and Risk Assessment: Potential for a Big
Mistake, 17 Vill. Envtl. L.J. 357, 386 (2006).
20. Gabriel Eckstein & George William Sherk, Alternative Strategies for Addressing the Presence and Effects of Pharmaceutical and Personal Care Products in
Fresh Water Resources, 15(2) Denv. Water L. Rev. 369-445 (2012).
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